Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202312002 A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy New Drug Phase Ⅲ
N202312003 A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) New Drug Phase Ⅰ
N202312027 A First-in-Human Study of Auger Molecular Therapy (AMT) in Patients with Malignant Cutaneous Lesions from Advanced Solid Tumors New Drug Phase Ⅰ
N202312039 A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Combined with Chemotherapy versus Rituximab Combined with Chemotherapy in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-2) New Drug Phase Ⅲ
N202312042 A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity New Drug Phase Ⅲ
N202312153 Safety and Efficacy of Finite versus Continuous Nucleos(t)ide Analogues Therapy in Patients with Chronic Hepatitis B:A Multicenter Randomized Controlled Trial New Drug NA
1 2 13 14 15 16 17 18 19 51 52 / 52

TOP